| __timestamp | Galapagos NV | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 111110000 | 46425000 |
| Thursday, January 1, 2015 | 129714000 | 81491000 |
| Friday, January 1, 2016 | 139574000 | 94291000 |
| Sunday, January 1, 2017 | 218502000 | 121827000 |
| Monday, January 1, 2018 | 322876000 | 160524000 |
| Tuesday, January 1, 2019 | 427320000 | 200000000 |
| Wednesday, January 1, 2020 | 523667000 | 275000000 |
| Friday, January 1, 2021 | 491707000 | 328100000 |
| Saturday, January 1, 2022 | 515083000 | 463800000 |
| Sunday, January 1, 2023 | 241294000 | 565000000 |
| Monday, January 1, 2024 | 731100000 |
Unleashing insights
In the ever-evolving landscape of biotechnology, innovation is the lifeblood that drives progress. Over the past decade, two industry leaders, Neurocrine Biosciences, Inc. and Galapagos NV, have demonstrated their commitment to research and development (R&D) with significant investments.
From 2014 to 2023, Galapagos NV consistently increased its R&D spending, peaking in 2020 with a remarkable 370% increase from its 2014 levels. However, a notable decline occurred in 2023, with expenditures dropping by over 50% from the previous year. In contrast, Neurocrine Biosciences, Inc. exhibited a steady upward trajectory, culminating in a 2023 investment that was 12 times its 2014 spending.
These trends highlight the dynamic nature of R&D investment strategies in the biotech sector, reflecting both the challenges and opportunities faced by companies in their quest for groundbreaking discoveries.
Comparing Innovation Spending: Amgen Inc. and Neurocrine Biosciences, Inc.
Comparing Innovation Spending: Gilead Sciences, Inc. and Galapagos NV
Comparing Innovation Spending: Neurocrine Biosciences, Inc. and Alkermes plc
R&D Spending Showdown: Neurocrine Biosciences, Inc. vs Rhythm Pharmaceuticals, Inc.
R&D Insights: How Neurocrine Biosciences, Inc. and CRISPR Therapeutics AG Allocate Funds
R&D Spending Showdown: Neurocrine Biosciences, Inc. vs Vericel Corporation
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
Neurocrine Biosciences, Inc. vs Dynavax Technologies Corporation: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: BioMarin Pharmaceutical Inc. vs Galapagos NV
TG Therapeutics, Inc. or Galapagos NV: Who Invests More in Innovation?
R&D Spending Showdown: Amicus Therapeutics, Inc. vs Galapagos NV
R&D Spending Showdown: Mesoblast Limited vs Galapagos NV